IRIS
BUGATTI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.391
AS - Asia 3.060
EU - Europa 2.173
SA - Sud America 468
Continente sconosciuto - Info sul continente non disponibili 366
AF - Africa 111
OC - Oceania 7
Totale 10.576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.241
CN - Cina 1.164
SG - Singapore 740
IE - Irlanda 475
VN - Vietnam 424
HK - Hong Kong 366
BR - Brasile 339
RU - Federazione Russa 303
DE - Germania 273
IT - Italia 260
FI - Finlandia 241
FR - Francia 134
UA - Ucraina 134
GB - Regno Unito 121
SE - Svezia 91
IN - India 74
CA - Canada 72
ZA - Sudafrica 60
BD - Bangladesh 53
AR - Argentina 34
MX - Messico 26
CO - Colombia 25
EC - Ecuador 24
AE - Emirati Arabi Uniti 23
JP - Giappone 23
ID - Indonesia 22
TR - Turchia 22
VE - Venezuela 21
ES - Italia 19
BE - Belgio 18
PK - Pakistan 18
NL - Olanda 17
IQ - Iraq 16
MY - Malesia 15
IR - Iran 14
PH - Filippine 14
PL - Polonia 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
JM - Giamaica 12
AT - Austria 11
CR - Costa Rica 10
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
TH - Thailandia 9
UZ - Uzbekistan 9
CL - Cile 8
PE - Perù 8
HN - Honduras 7
KE - Kenya 7
IL - Israele 6
AL - Albania 5
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
DZ - Algeria 4
EE - Estonia 4
GR - Grecia 4
KZ - Kazakistan 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
CU - Cuba 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
JO - Giordania 3
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
UY - Uruguay 3
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
HU - Ungheria 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
MQ - Martinica 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
BB - Barbados 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
KH - Cambogia 1
Totale 10.199
Salva come PNG Salva come JPEG
Città #
San Jose 537
Dublin 467
Chandler 415
Singapore 397
Ashburn 354
Hong Kong 352
Dallas 326
Council Bluffs 282
Beijing 252
Jacksonville 198
Nanjing 195
Ho Chi Minh City 138
Boardman 124
Helsinki 113
Hanoi 106
New York 105
Munich 102
Lauterbourg 101
Los Angeles 98
Princeton 87
Lawrence 75
Wilmington 75
Nanchang 68
Ann Arbor 64
Santa Clara 64
Shenyang 59
Shanghai 58
Medford 51
Milan 51
Hebei 50
Changsha 49
Johannesburg 49
Moscow 49
Da Nang 45
Buffalo 43
Redondo Beach 42
Turku 42
Jiaxing 36
Columbus 30
Pavia 30
São Paulo 30
Montreal 27
Hangzhou 25
Orem 24
Tianjin 21
Tokyo 20
Dubai 19
Piscataway 19
Seattle 19
Toronto 19
Woodbridge 19
Brussels 18
London 18
The Dalles 18
Atlanta 17
Chennai 17
Denver 17
Rio de Janeiro 17
Phoenix 16
Brooklyn 15
Frankfurt am Main 14
Chicago 13
Rome 13
Haiphong 12
Stockholm 12
Tabriz 12
Warsaw 12
Fairfield 11
Falkenstein 11
Manchester 11
Newark 11
Norwalk 11
Nuremberg 11
Mexico City 10
Poplar 10
Quito 10
Washington 10
Belo Horizonte 9
Guangzhou 9
Houston 9
Baghdad 8
Medellín 8
Mumbai 8
Philadelphia 8
San José 8
Verona 8
Zhengzhou 8
Amsterdam 7
Bari 7
Berlin 7
Guayaquil 7
Phủ Lý 7
San Francisco 7
Bangkok 6
Biên Hòa 6
Brasília 6
Brno 6
Bến Tre 6
Dhaka 6
Elk Grove Village 6
Totale 6.535
Salva come PNG Salva come JPEG
Nome #
B cells in rheumatoid arthritis. 161
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 156
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 152
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 151
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 149
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 147
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 144
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 133
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 132
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 130
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 128
B cells in rheumatoid arthritis. 128
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 126
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 125
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 123
B cell autoimmunity and bone damage in rheumatoid arthritis 121
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 121
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 119
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 118
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 117
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 114
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 114
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 113
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 112
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 111
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 109
Adult-onset Still's disease with elderly onset, results from a multicentre study 109
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 108
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 107
Insights Into the Concept of Rheumatoid Arthritis Flare 104
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study 103
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 102
Long term treatment of rheumatoid arthritis with rituximab 100
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 100
Established rheumatoid arthritis. The pathogenic aspects. 100
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 99
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 99
Long term treatment of rheumatoid arthritis with rituximab. 98
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 98
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 98
null 97
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 97
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 96
High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis 96
Seronegative autoimmune diseases: A challenging diagnosis 96
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 96
Nuovi aspetti patogenetici dell’artrite reumatoide 95
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 95
Early treatment in early undifferentiated arthritis 95
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 95
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 94
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 94
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 94
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 93
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 93
Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat 92
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 92
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 91
Anti-neutrophil cytoplasmic antibodies (ANCA) 90
Synovial tissue heterogeneity and peripheral blood biomarkers 90
Tumor necrosis factor-α inhibitor-related autoimmune disorders 87
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist 87
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 87
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 87
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 87
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 86
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 86
Tender joints in early autoantibody-negative rheumatoid arthritis: Should they be included in the scoring of joint involvement of the 2010 ACR/EULAR classification criteria? 83
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 83
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 83
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 82
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 82
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 82
Differences and similarities in rheumatology specialty training programmes across European countries 82
Clinical Applications of Synovial Biopsy. 81
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 80
Long-term safety of abatacept in patients with rheumatoid arthritis 79
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 79
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 77
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 77
Rheumatology training experience across Europe: Analysis of core competences 76
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 76
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 76
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 74
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 74
Seronegative rheumatoid arthritis: one year in review 2023 73
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 73
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 73
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 73
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 72
La linfoneogenesi 72
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 71
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 71
Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice 70
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 70
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs 69
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 67
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 63
The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis 61
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors 61
Totale 9.732
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.106
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.106
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022343 0 0 0 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/20251.775 43 111 24 24 21 110 124 101 468 94 236 419
2025/20264.084 307 273 458 374 461 147 862 228 325 279 203 167
2026/2027964 70 250 305 339 0 0 0 0 0 0 0 0
Totale 10.576